ONCAlert | 2018 ASCO Annual Meeting
Colorectal Cancer Case Studies

Charles Fuchs, MD: Percentage of RAS Mutation Tests in Metastatic CRC

Charles Fuchs, MD
Published Online:Apr 28, 2016
Case 2 examines a 52-year-old woman newly diagnosed with metastatic CRC who is genotyped as part of her initial work up.

Unresectable Colon Cancer with Charles Fuchs, MD and Tanios Bekaii-Saab, MD: Case 2

Unresectable Colon Cancer with Charles Fuchs, MD and Tanios Bekaii-Saab, MD: Case 1
Unresectable Colon Cancer with Charles Fuchs, MD and Tanios Bekaii-Saab, MD: Case 2
Unresectable Colon Cancer with Charles Fuchs, MD and Tanios Bekaii-Saab, MD: Case 1
Unresectable Colon Cancer with Charles Fuchs, MD and Tanios Bekaii-Saab, MD: Case 2


What are the data on the percentage of patients with metastatic CRC who currently are tested for RAS mutations? 

As I mentioned, the proportion of patients who have RAS mutated tumors are now over 50% because we're doing so many tests as compared to what we did initially, when we used to do just EXON 2 KRAS and it was about 35% to 40%. Now that we're doing all KRAS and all NRAS mutations, the rates of RAS mutations 50% to 52%. We would be missing a lot of patients if we only do CODONs 12 and 13 of KRAS. It's important that we do all RAS testing.

Unresectable Colon Cancer: Case 2

52-year-old woman newly diagnosed with metastatic CRC and is genotyped as part of her initial work up.

Publications
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.